Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Stemmer SM, Steiner M, Rizel S, Geffen DB, Nisenbaum B, Peretz T, Soussan-Gutman L, Bareket-Samish A, Isaacs K, Rosengarten O, Fried G, McCullough D, Svedman C, Shak S, Liebermann N, Ben-Baruch N. Stemmer SM, et al. Among authors: rizel s. NPJ Breast Cancer. 2017 Sep 8;3:32. doi: 10.1038/s41523-017-0033-7. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28900632 Free PMC article.
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N. Stemmer SM, et al. Among authors: rizel s. Breast Cancer Res Treat. 2013 Jul;140(1):83-92. doi: 10.1007/s10549-013-2603-1. Epub 2013 Jun 26. Breast Cancer Res Treat. 2013. PMID: 23801158 Free PMC article. Clinical Trial.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N. Stemmer SM, et al. Among authors: rizel s. NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28900633 Free PMC article.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Stemmer SM, Steiner M, Rizel S, Ben-Baruch N, Uziely B, Jakubowski DM, Baron J, Shak S, Soussan-Gutman L, Bareket-Samish A, Fried G, Rosengarten O, Itay A, Nisenbaum B, Katz D, Leviov M, Tokar M, Liebermann N, Geffen DB. Stemmer SM, et al. Among authors: rizel s. NPJ Breast Cancer. 2019 Nov 8;5:41. doi: 10.1038/s41523-019-0137-3. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31728408 Free PMC article.
Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
Yerushalmi R, Goldvaser H, Sulkes A, Ben-Aharon I, Hendler D, Neiman V, Ciuraru NB, Bonilla L, Amit L, Zer A, Granot T, Rizel S, Stemmer SM. Yerushalmi R, et al. Among authors: rizel s. PLoS One. 2014 Oct 15;9(10):e107273. doi: 10.1371/journal.pone.0107273. eCollection 2014. PLoS One. 2014. PMID: 25330205 Free PMC article.
63 results